The Global EYLEA drug market primarily includes anti-VEGF drugs used in the treatment of retinal diseases such as age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). EYLEA, developed by Regeneron Pharmaceuticals and Bayer, is a human monoclonal antibody designed for intravitreal administration that targets and inhibits VEGF-A and PlGF. The drug has revolutionized the treatment of common back-of-the-eye diseases and has minimal adverse effects.

The Global EYLEA Drug Market Size Is Estimated To Be Valued At US$ 8.79 Bn In 2024 And Is Expected To Exhibit A CAGR Of 7.2% Over The Forecast Period 2024-2031.

Key players operating in the Global EYLEA Drug market are Regeneron Pharmaceuticals, Bayer, Coherus BioSciences, Inc., and Klinge Biopharma. Regeneron Pharmaceuticals dominates the market with over 90% market share owing to its early approval and wide usage of EYLEA for various back-of-the-eye diseases. The growing demand for anti-VEGF drugs for back-of-the-eye diseases and rising geriatric population suffering from retinal disorders will aid in market expansion during the forecast period.

Geographically, North America has the largest market for EYLEA drugs currently owing to high patient awareness levels and healthcare expenditure. However, Asia Pacific market is expected to witness fastest growth during the forecast period due to rising incidence of diabetes, growing economies, and increasing healthcare spending in the region.

Key Takeaways:

Key players operating in the Global EYLEA Drug market are Regeneron Pharmaceuticals, Bayer, Coherus BioSciences, Inc., and Klinge Biopharma. Regeneron Pharmaceuticals dominates the market with over 90% market share owing to its early approval and wide usage of EYLEA for various back-of-the-eye diseases. The growing demand for anti-VEGF drugs for back-of-the-eye diseases and rising geriatric population suffering from retinal disorders will aid in market expansion during the forecast period.

The rising prevalence of diabetes and obesity have significantly increased the risk of developing back-of-the-eye diseases such as DME and DR. According to the International Diabetes Federation, approximately 537 million adults aged 20-79 years were living with diabetes in 2021 and the number is expected to rise to 643 million by 2031 and 783 million by 2045. This rising disease prevalence will augment the demand for EYLEA drugs for effective treatment of various retinal disorders.

North America and Europe currently dominate the global EYLEA drug market but Asia Pacific is anticipated to offer lucrative opportunities. Countries like China and India are expected to emerge as high growth potential markets during the forecast period owing to increasing healthcare infrastructure, growing medical tourism, and rising healthcare expenditure in these countries.

Market Drivers:

Rising prevalence of diabetes is a major factor driving the demand for EYLEA drugs. Uncontrolled diabetes, especially in geriatric population, increases the risk of retinal disorders tremendously. According to the International Agency for the Prevention of Blindness, the number of people diagnosed with diabetic retinopathy (DR) is expected to increase from 126.6 million in 2021 to 191.0 million by 2031 owing to growing diabetic population worldwide. EYLEA as an anti-VEGF agent has shown high efficacy in treatment of DME and DR associated vision loss and its adoption is expected to increase significantly during the forecast period.

The current geopolitical situation is impacting the growth of the global EYLEA drug market. Global tensions and trade restrictions between major economies are disrupting supply chains and access to critical materials needed for drug production. Manufacturers are facing challenges in procuring active pharmaceutical ingredients and other raw materials from sanctioned countries. This is leading to shortages and delays in fulfillment. To mitigate risks, companies need to diversify their supplier networks and establish secondary sourcing options in friendly nations. Localizing more aspects of production can help address political uncertainties. Partnerships and contract manufacturing deals within allied regions can enhance security of supply. Building emergency stockpiles of key materials can also help prepare for potential future disruptions. Investing in automated and flexible manufacturing facilities can make operations more resilient to geopolitical shocks. Overall, the industry requires strengthening alternative supply routes, localizing production dependencies, and building operational agility to address geopolitical vulnerabilities and sustain growth over the long term.

Geographically, North America accounts for the major share of the global EYLEA drug market in terms of value. This is attributed to factors such as the high adoption of advanced treatment options, presence of major manufacturers, and availability of favorable reimbursement policies for ophthalmic drugs. The U.S. commands the largest market share in North America due to the rising prevalence of back-of-the-eye diseases and increasing access to sophisticated healthcare infrastructure. Europe holds the second position supported by growing public awareness about eye care and availability of widened treatment choices. On the other hand, Asia Pacific is projected to witness the fastest growth during the forecast period owing to the large patient pool, improving access to healthcare facilities, and rising healthcare expenditures. Rising medical tourism in Asia's developing nations will further aid the expansion of the regional market.

What are the key data covered in this Global EYLEA Drug Market report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Global EYLEA Drug Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Global EYLEA Drug Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behavior

:- Global EYLEA Drug Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Global EYLEA Drug Market vendors

FAQ’s

Q.1 What are the main factors influencing the Global EYLEA Drug market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global EYLEA Drug Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global EYLEA Drug market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?

Get more insights on this topic: https://www.feedsfloor.com/pharmaceuticals/medical-treatment-monoclonal-antibody-therapies-will-drive-growth-eylea-drug-market